Prostate Cancer (Diagnosis)
44
24
25
7
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 44 trials
100.0%
+13.4% vs benchmark
2%
1 trials in Phase 3/4
0%
0 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 7 completed trials
Clinical Trials (44)
TENS During Transperineal Prostate Biopsy
Investigation of an Intelligent Centre-adaptive Multi-modal Fusion Framework (Cad- MMFF) to Overcome Unnecessary Prostate Biopsies and Optimize MRI Utilization
miRNA Panel for PCa Diagnosis
Validation of a Platelet Proteomic Assay for Diagnosing and Monitoring Prostate Cancer
High Cardiovascular Risk Intervention With Cardio-Oncology Consultation for Prostate Cancer Following Androgen Receptor Pathway Inhibitor (ARPI) Therapy (Heart-Safe)
Improving Cryoablation Efficacy With BARRigel Rectal Spacing (ICE-BARR)
Development and Validation of a Non-Invasive AI Diagnostic Model for Prostate Cancer Using Multiparametric MRI and PSMA PET/CT
Intraprostatic Anesthesia During Transperineal Prostate Biopsy
Evaluating the Implementation of a Comprehensive Multilevel Virtual Oncology Program Among Veterans Diagnosed With Lung, Colorectal, Prostate, and Breast Cancers in the US Department of Veterans Affairs
Early Diagnosis of PROstate CANcer for Black Men
Investigating the Safety and Diagnostic Performance of 68Ga-NYM032 Injection PET/CT in Men With Newly Diagnosed Prostate Cancer.
Multimodal Imaging and Digital Pathology for Prostate Cancer Prediction
MagneThermoPro : Magnetic Resonance Thermography of Human Prostate
Theranostic Applications of Radionuclides in Prostate Cancer
Plasma Exosomal RNA Signature for Prostate Cancer Bone Metastasis
The Enhancement of Diagnostic and Grading Efficacy of Prostate Cancer by New MRI Sequences: A Prospective Observational Study Based on New MRI Sequences in a Single Center
Study of the Epidemiological, Clinical, Diagnostic, and Therapeutic Characteristics of Prostate Cancers in Algeria
Prognostic Value of Early Postoperative Prostate-Specific Antigen for Oncological Outcomes After Radical Prostatectomy
Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617
INSIGHT-PCa: MRI- and PHI-Guided Risk-Adapted Strategy for Prostate Cancer Diagnosis